id: NEW:alcohol_associated_fatty_liver_to_NEW:alcohol_associated_cirrhosis
name: Alcohol-Associated Fatty Liver â†’ Alcohol-Associated Cirrhosis
from_node:
  node_id: NEW:alcohol_associated_fatty_liver
  node_name: Alcohol-Associated Fatty Liver
to_node:
  node_id: NEW:alcohol_associated_cirrhosis
  node_name: Alcohol-Associated Cirrhosis
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Alcohol-associated fatty liver (steatosis) develops as initial hepatic response to alcohol'
- 'Step 2: Continued alcohol exposure leads to steatohepatitis with inflammation'
- 'Step 3: Persistent inflammation activates fibrogenic pathways in hepatic stellate cells'
- 'Step 4: Progressive fibrosis advances to cirrhosis with permanent architectural changes'
evidence:
  quality_rating: A
  n_studies: 35
  primary_citation: 'Sachin Amonker et al. 2023. "Prevalence of alcohol-associated liver disease: a systematic
    review and meta-analysis." https://doi.org/10.1097/HC9.0000000000000133'
  supporting_citations:
  - Additional citations require full-text access
  - Meta-analysis separately quantified 18,844 cases of alcohol-associated fatty liver
  - 502 cases of alcohol-associated cirrhosis documented across included studies
  doi: 10.1097/HC9.0000000000000133
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The meta-analysis separately quantified fatty liver (18,844 cases) and cirrhosis (502 cases),
  reflecting the disease progression spectrum. Fatty liver represents early reversible disease that can
  progress to irreversible cirrhosis with continued alcohol exposure.
quantitative_effects:
  sample_size: 513278
structural_competency:
  equity_implications: The separation of fatty liver and cirrhosis in this analysis identifies a critical
    intervention window. Structural interventions that enable early detection and treatment of fatty liver
    - including healthcare access, AUD treatment availability, and routine screening protocols - could
    prevent progression to cirrhosis. The dramatic difference in case counts (18,844 fatty liver vs 502
    cirrhosis) suggests many with early disease never progress, indicating prevention opportunities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.421498'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
